Welcome to the STOPENTERICS website
STOPENTERICS is a European consortium which has received funding from the European Community's Seventh Framework Programme (FP7/2007-2013).
STOPENTERICS aims to provide novel prophylactic solutions by imposing a two-fold paradigm switch in the development of vaccine candidates against Shigella and ETEC:
• to break the dogma of serotype-specific protection and
• to improve the immunogenicity of some already identified antigens.
In addition, since a set of new vaccine candidates corresponding to novel strategies have already reached an advanced stage, the consortium is in a position to achieve a proof of concept early on in the program. The program integrates basic research, particularly genomics, transcriptomics, proteomics, high-throughput technologies, and synthetic chemistry to identify novel antigens and generate new vaccine formulations, as well as immunology and development of cell-based and animal models to help rationalize R&D and prepare for transition to phase 1 trials. A particular effort will be dedicated, throughout the program, to immunomonitoring of natural Shigella and ETEC infections in order to generate and validate novel and reliable correlates of protection. Therefore, STOPENTERICS will adopt a pragmatic modus operandi illustrated by the strong momentum imposed to bring innovative candidates as quickly as possible through the R&D pipeline, including clinical trials carried out both in the North and in the South.
Key words: Shigella, ETEC, enteric infection, dysentery, vaccines, O-polysaccharides, synthetic sugars, conjugate vaccines, protein-based vaccines, immunomonitoring, experimental infection, experimental protection, clinical trials, training/e-learning
HSeT content and learning activities are available under a
Creative Commons Attribution - Noncommercial - No
Derivative Works 3.0 License
This site complies with the HONcode standard for trustworthy health information:
Last update: Sunday, March 24, 2013Contact